# Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

> **NCT06723405** · PHASE2 · COMPLETED · sponsor: **Evommune, Inc.** · enrollment: 71 (actual)

## Conditions studied

- Atopic Dermatitis (AD)
- Eczema
- Eczema Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** EVO301
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06723405
- **Lead sponsor:** Evommune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-13
- **Primary completion:** 2025-11-17
- **Final completion:** 2025-11-17
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723405, "Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06723405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*